Anti-wrinkle cream

Abstract

Disclosed is an anti-wrinkle cream, comprising, in percentages by mass: 0.3%-2.5% of a Radix pseudostellariae cyclic peptide solution, 1.0%-5.0% of a cone snail cyclic peptide solution, 0.1%-5.0% of a Pichia pastoris recombinant collagen solution, and 1.0%-5.0% of a mixed solution of hydrolyzed collagen and hexapeptide-9.

Description

Anti-wrinkle face cream

[0001] Cross-reference to related applications

[0002] This application claims priority to Chinese Patent Application No. 2025103634172, filed on March 25, 2025, entitled "Anti-wrinkle face cream", the entire contents of which are incorporated herein by reference. Technical Field

[0003] This disclosure relates to the field of cosmetics, and more specifically, to an anti-wrinkle face cream. Background Technology

[0004] Currently, anti-wrinkle cosmetics typically contain single peptide ingredients such as acetyl peptides and palmitoyl peptides; however, the anti-wrinkle effect of these common peptide cosmetics is limited and can no longer meet the market's increasingly demanding anti-wrinkle requirements. Summary of the Invention

[0005] The purpose of this disclosure is to provide an anti-wrinkle face cream.

[0006] In a first aspect, this disclosure provides an anti-wrinkle face cream, which, by weight percentage, comprises: 0.3%-2.5% of Codonopsis pilosula cyclic peptide solution, 1.0%-5.0% of Conophytum comosum cyclic peptide solution, 0.1%-5.0% of Pichia pastoris recombinant collagen solution, and 1.0%-5.0% of a mixed solution of hydrolyzed collagen and hexapeptide-9.

[0007] In the aforementioned technical solution, the anti-wrinkle cream innovatively employs a combination of bicyclic peptides; simultaneously, it is formulated with recombinant collagen and marine collagen oligopeptides (hydrolyzed collagen and hexapeptide-9), achieving multi-dimensional anti-wrinkle and wrinkle-reducing effects, including: promoting collagen production, increasing SPARC in the dermis, increasing fibrin levels in the dermis, inhibiting the transmission of skin nerve signals and inhibiting the activity of collagenase, thereby effectively improving the efficacy of inhibiting skin aging. The various ingredients in this anti-wrinkle cream work synergistically to achieve a synergistic effect; furthermore, each ingredient exhibits high bioactivity and good stability, enhancing the true anti-wrinkle effect of the cosmetic.

[0008] In other embodiments of this disclosure, the anti-wrinkle cream comprises, by weight percentage: 0.5%-2.0% of Codonopsis pilosula cyclic peptide solution, 1.5%-4.0% of Conophytum comosum cyclic peptide solution, 0.5%-4.0% of Pichia pastoris recombinant collagen solution, and 1.5%-5.0% of a mixed solution of hydrolyzed collagen and hexapeptide-9.

[0009] In other embodiments of this disclosure, the Codonopsis pilosula cyclic peptide solution comprises: glycerol, water, and Codonopsis pilosula extract; optionally, the Codonopsis pilosula extract in the Codonopsis pilosula cyclic peptide solution has a mass percentage of 0.1% to 0.3%.

[0010] In other embodiments of this disclosure, the conocysteine ​​solution comprises: water, 1,2-pentanediol, 1,2-hexanediol, and conocysteine; optionally, the mass percentage of conocysteine ​​in the conocysteine ​​solution is 0.1% to 5%.

[0011] In other embodiments of this disclosure, the Pichia pastoris recombinant collagen solution comprises: water, glycerol, sodium dihydrogen phosphate, disodium hydrogen phosphate, and soluble collagen. Optionally, the soluble collagen in the Pichia pastoris recombinant collagen solution comprises 0.1% to 5% by mass.

[0012] In other embodiments of this disclosure, the Pichia pastoris recombinant collagen uses amino acids 1076-1202 of human type I collagen and amino acids 594-846 of type III collagen as templates for human collagen.

[0013] In other embodiments of this disclosure, the mixture solution of hydrolyzed collagen and hexapeptide-9 comprises: water, glycerol, sodium PCA, erythritol, carrageenan powder, xanthan gum, hydrolyzed collagen, hexapeptide-9, benzoic acid, and sorbic acid.

[0014] In other embodiments of this disclosure, the anti-wrinkle cream further includes: a primary emulsifier; the primary emulsifier is a low-melting-point C12-20 acid PEG-8 ester.

[0015] In other embodiments of this disclosure, the anti-wrinkle cream further includes: shea butter and cetearyl alcohol.

[0016] In other embodiments of this disclosure, the anti-wrinkle cream further includes: isononyl isononanoate, polydimethylsiloxane, and ammonium acryloyldimethyltaurate / VP copolymer. Detailed Implementation

[0017] To make the objectives, technical solutions, and advantages of the embodiments of this disclosure clearer, the technical solutions in the embodiments of this disclosure will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0018] The inventors discovered that anti-wrinkle cosmetics containing peptides such as acetyl peptides and palmitoyl peptides have a single anti-wrinkle pathway, limiting their effectiveness. Further research revealed that the primary cause of wrinkles lies in the aging of the dermal structure; therefore, protecting the dermal structure becomes crucial for effective anti-wrinkle treatment. Further research showed that SPARC plays a vital role in maintaining the structural integrity of the skin and contributes to multiple processes involved in skin development, maintenance, and repair. The level of fibrin I in the dermis affects the maturity and structure of the skin matrix. Further research also found that the transmission of nerve signals in the skin affects dermal structure; and the activity of collagenase also influences dermal structure and collagen production. Therefore, improving dermal structure requires a multi-dimensional approach.

[0019] Based on the above research, this disclosure provides an anti-wrinkle face cream, which, by weight percentage, comprises: 0.3%-2.5% Codonopsis pilosula cyclic peptide solution, 1.0%-5.0% Conophytum comosum cyclic peptide solution, 0.1%-5.0% Pichia pastoris recombinant collagen solution, and 1.0%-5.0% mixed solution of hydrolyzed collagen and hexapeptide-9.

[0020] In the above technical solution, the various components work synergistically to achieve a synergistic effect. It improves the dermal structure from different dimensions, increasing SPARC in the dermis and thus enhancing the synthesis of type I collagen. Simultaneously, it inhibits the transmission of skin nerve signals and the activity of collagenase, promoting collagen production. This achieves multi-dimensional and truly effective protection of the dermal structure, greatly improving the anti-aging effect.

[0021] Furthermore, the following active ingredients work synergistically to improve dermal structure: Codonopsis pilosula cyclic peptide: increases type I collagen synthesis, improves dermal structure; increases SPARC in the dermis, enhancing skin matrix maturity and structure; increases fibrin I levels in the dermis; Conocospira cyclic peptide: inhibits the transmission of nerve signals in the skin; Pichia pastoris recombinant collagen: inhibits collagenase activity; a mixture of hydrolyzed collagen and hexapeptide-9: promotes collagen production. These four active ingredients work together from different dimensions to truly improve dermal structure and greatly enhance anti-aging effects.

[0022] Furthermore, the anti-wrinkle cream disclosed herein innovatively employs a combination of bicyclic peptides; it is also formulated with recombinant collagen and marine collagen oligopeptides; each ingredient has high bioactivity and good stability, thereby enhancing the true anti-wrinkle effect of the cosmetic.

[0023] For example, in some embodiments of this disclosure, the anti-wrinkle cream, by weight percentage, comprises: 0.3%, 0.4%, 0.5%, 0.8%, 1%, 1.3%, 1.5%, 1.8%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5% of a Codonopsis pilosula cyclic peptide solution, or any range between any two of the aforementioned values; and 1.0%, 1.2%, 1.5%, 1.8%, 2.0%, 2.2%, 2.5%, 2.8%, 3.0%, 3.2%, 3.5%, 3.8%, 4.0%, 4.2%, 4.5%, 4.8%, 4.9%, 5.0% of a conocozoide cyclic peptide solution, or any two of the aforementioned values. The range between any two values; 0.1%, 0.2%, 0.3%, 0.5%, 0.8%, 1.0%, 1.2%, 1.5%, 1.8%, 2.0%, 3.0%, 4.0%, 4.5%, 5.0% of Pichia pastoris recombinant collagen solution, or the range between any two of the aforementioned values; 1.0%, 1.2%, 1.5%, 1.8%, 2.0%, 2.2%, 2.5%, 2.8%, 3.0%, 3.2%, 3.5%, 3.8%, 4.0%, 4.2%, 4.5%, 4.8%, 4.9%, 5.0% of a mixed solution of hydrolyzed collagen and hexapeptide-9, or the range between any two of the aforementioned values.

[0024] Furthermore, in some embodiments of this disclosure, the anti-wrinkle cream comprises, by weight percentage: 0.5%-2.0% of Codonopsis pilosula cyclic peptide solution, 1.5%-4.0% of Conophytum comosum cyclic peptide solution, 0.5%-4.0% of Pichia pastoris recombinant collagen solution, and 1.5%-5.0% of a mixed solution of hydrolyzed collagen and hexapeptide-9.

[0025] Exemplary examples, in some embodiments of this disclosure, the anti-wrinkle face cream, by weight percentage, comprises: 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0% of a Codonopsis pilosula cyclic peptide solution, or any range between two of the aforementioned values; and 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0% of a Conocospira cyclic peptide solution. 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, or any range between any two of the aforementioned values; 0.5%, 0.8%, 1%, 1.2%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, or any range between any two of the aforementioned values ​​for a Pichia pastoris recombinant collagen solution; 1.5%, 1.6%, 1.8%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, or any range between any two of the aforementioned values ​​for a mixed solution of hydrolyzed collagen and hexapeptide-9.

[0026] In the aforementioned technical solution, the *Pseudostellaria heterophylla* cyclic peptide compounded in the anti-wrinkle cream is found only in the bioactive cyclic peptide Heterophyllin B of *Pseudostellaria heterophylla*. It possesses excellent stability, bioactivity, and cell permeability, effectively promoting the skin matrix and regulating epidermal homeostasis, increasing collagen synthesis, improving dermal structure, and enhancing skin matrix maturity and structure. Through retinol-like metabolism and appropriate characteristics, it restarts collagen production and improves epidermal structure, exceeding the skincare benefits of retinol. It significantly reduces sagging while firming the skin and reducing uneven skin tone in middle-aged women. Combining this *Pseudostellaria heterophylla* cyclic peptide with other ingredients can achieve a synergistic effect, greatly enhancing the anti-wrinkle effect of the anti-wrinkle cream.

[0027] Furthermore, in some embodiments of this disclosure, the conocoid cyclic peptide compounded in the anti-wrinkle cream is a biomimetic cyclic peptide derived from natural conocoid polypeptides. It is highly stable and has strong bioactivity. Through the spatial and electrostatic interactions of the disulfide bond backbone, it blocks ion channels, thereby selectively inhibiting voltage-gated sodium channels. This reduces the efficiency of excitable cells in generating action potentials, thereby reducing the efficiency of electrical signal propagation in nerves. It can significantly improve skin smoothness and roughness, enhance fibroblast activity, promote the production of type I collagen, and increase skin elasticity. Combining this conocoid cyclic peptide with other ingredients can achieve a synergistic effect, greatly enhancing the anti-wrinkle effect of the anti-wrinkle cream.

[0028] Furthermore, in some embodiments of this disclosure, the Pichia pastoris recombinant collagen compounded in the anti-wrinkle cream uses amino acids 1076-1202 of human type I collagen and amino acids 594-846 of type III collagen as templates for human collagen. The nucleotide sequence of the collagen was optimized using translation pause theory, and a recombinant human collagen gene expression vector was constructed using molecular biology techniques. The recombinant human collagen was solublely expressed in yeast cells, and high-purity recombinant human collagen was isolated and purified. Collagen can be used to treat burns, trauma, and corneal diseases; it also has wide applications in cosmetics, tissue repair, and drug sustained-release agents. In the cosmetics field, collagen is an important component of the skin extracellular matrix, possessing moisturizing, skin barrier strengthening, collagen replenishment, and anti-aging effects. Combining this Pichia pastoris recombinant collagen with other ingredients can achieve a synergistic effect, greatly enhancing the anti-wrinkle effect of the anti-wrinkle cream.

[0029] Furthermore, in some embodiments of this disclosure, the mixture of hydrolyzed collagen and hexapeptide-9 in the anti-wrinkle cream mainly comprises marine collagen oligopeptides, red seaweed extract, naturally fermented erythritol, and RSPO glycerin. This high proportion of naturally derived ingredients is biodegradable, enhances skin hydration and barrier function, promotes the expression of collagen I, collagen III, collagen IV, and collagen XVII, thus slowing down aging and leaving skin smooth and delicate. Combining this mixture of hydrolyzed collagen and hexapeptide-9 with other ingredients can achieve a synergistic effect, greatly enhancing the anti-wrinkle effect of the anti-wrinkle cream.

[0030] The four active ingredients in the anti-wrinkle cream disclosed herein not only achieve a synergistic effect, but also exhibit high bioactivity and strong stability when formulated together, thereby further enhancing the anti-wrinkle effect of the cream. Furthermore, the four active ingredients in the aforementioned anti-wrinkle cream achieve multi-channel, multi-target anti-wrinkle effects through different anti-wrinkle pathways, significantly improving the anti-wrinkle efficacy of the cream.

[0031] Furthermore, in some embodiments of this disclosure, the Codonopsis pilosula cyclic peptide solution comprises: glycerol, water, and Codonopsis pilosula extract.

[0032] It should be noted that the Codonopsis pilosula extract in the above-mentioned Codonopsis pilosula cyclic peptide solution is mainly the bioactive cyclic peptide Heterophyllin B present in Codonopsis pilosula.

[0033] Further optionally, in some embodiments of this disclosure, the mass percentage of *Pseudostellaria heterophylla* extract in the aforementioned *Pseudostellaria heterophylla* cyclic peptide solution is 0.1% to 0.3% by mass. Exemplarily, in some embodiments of this disclosure, the mass percentage of *Pseudostellaria heterophylla* extract in the aforementioned *Pseudostellaria heterophylla* cyclic peptide solution is 0.1%, 0.11%, 0.12%, 0.13%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.28%, 0.3%, or a range between any two of the aforementioned values.

[0034] Glycerin and water in the Codonopsis pilosula cyclic peptide solution are both used as solvents, and there are no restrictions on their ratio; they can be added as needed.

[0035] Further optionally, in some embodiments of this disclosure, the composition of the above-mentioned Codonopsis pilosula cyclic peptide solution, by mass percentage, is: 75-85% glycerol; 15-25% water; and 0.1-0.3% Codonopsis pilosula extract.

[0036] For example, in some embodiments of this disclosure, the aforementioned ginseng cyclic peptide can be selected from the ginseng cyclic peptide with the trade name CycloRetin™.

[0037] Furthermore, in some embodiments of this disclosure, the conocycline solution comprises: water, 1,2-pentanediol, 1,2-hexanediol, and conocycline.

[0038] It should be noted that the conopod peptides in the above-mentioned conopod cyclic peptide solution are mainly biomimetic cyclic peptides derived from natural conopod polypeptides.

[0039] Further optionally, in some embodiments of this disclosure, the conopodyl cyclic peptide solution contains 0.1% to 5% conopodyl peptide by mass percentage. Exemplarily, in some embodiments of this disclosure, the conopodyl peptide solution contains 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.8%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, or a range between any two of the aforementioned values. Further optionally, the conopodyl peptide solution contains 0.1% to 0.3% conopodyl peptide by mass percentage.

[0040] Water, 1,2-pentanediol, and 1,2-hexanediol in the conocyclopeptide solution are all used as solvents, and their respective proportions are not restricted; they can be added according to actual needs.

[0041] Further optionally, in some embodiments of this disclosure, the composition of the above-mentioned conotoxin solution, by mass percentage, is: 35-45% 1,2-pentanediol; 35-45% 1,2-hexanediol; 15-25% water; and 0.1%-10% Codonopsis pilosula extract. Exemplarily, in some embodiments of this disclosure, the above-mentioned conotoxin is selected from the conotoxin product manufactured by Shenzhen Viki Science & Technology Co., Ltd. under the trade name Mu-conotoxin CnIIIC.

[0042] Furthermore, in some embodiments of this disclosure, the Pichia pastoris recombinant collagen solution comprises: water, glycerol, sodium dihydrogen phosphate, disodium hydrogen phosphate, and soluble collagen.

[0043] It should be noted that the soluble collagen in the Pichia pastoris recombinant collagen solution mentioned above uses amino acids 1076-1202 of human type I collagen and amino acids 594-846 of type III collagen as templates for human collagen. The nucleotide sequence of the collagen was optimized using the theory of translation pausing, and a recombinant human collagen gene expression vector was constructed using molecular biology techniques. Recombinant human collagen was solublely expressed in Pichia pastoris cells, and high-purity recombinant human collagen was isolated and purified.

[0044] Further optionally, in some embodiments of this disclosure, the soluble collagen in the above-mentioned Pichia pastoris recombinant collagen solution is 0.1% to 5% by mass percentage. Exemplarily, in some embodiments of this disclosure, the soluble collagen in the above-mentioned Pichia pastoris recombinant collagen solution is 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.8%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, or a range between any two of the aforementioned values. Further optionally, the soluble collagen in the Pichia pastoris recombinant collagen solution is 0.1% to 0.3% by mass. Water, glycerol, sodium dihydrogen phosphate, and disodium hydrogen phosphate in the Pichia pastoris recombinant collagen solution are all used as solvents, and their respective proportions are not limited; they can be added according to actual needs. For example, in some embodiments of this disclosure, the Pichia pastoris recombinant collagen solution described above is selected from Pichia pastoris recombinant collagen with the trade name HydroCol-y produced by Guangdong Marubi Biotechnology Co., Ltd.

[0045] Further optionally, in some embodiments of this disclosure, the soluble collagen in the Pichia pastoris recombinant collagen solution is prepared according to the method in patent CN110484519B "Application of Pichia pastoris translation-related factor Bcy1 in exogenous protein expression".

[0046] Furthermore, in some embodiments of this disclosure, the mixture solution of hydrolyzed collagen and hexapeptide-9 includes: water, glycerol, sodium PCA, erythritol, carrageenan powder, xanthan gum, hydrolyzed collagen, hexapeptide-9, benzoic acid, and sorbic acid.

[0047] It should be noted that the carrageenan powder in the above-mentioned mixture solution is mainly a red seaweed extract; hexapeptide-9 mainly contains marine collagen oligopeptides.

[0048] Further optionally, in some embodiments of this disclosure, the total mass percentage of hydrolyzed collagen powder (CHONDRUS CRISPUS) and hexapeptide-9 in the above-mentioned mixture solution is 0.1% to 5% by mass percentage. Exemplarily, in some embodiments of this disclosure, the total mass percentage of hydrolyzed collagen powder and hexapeptide-9 in the above-mentioned mixture solution is 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.8%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, or a range between any two of the aforementioned values. Hydrolyzed collagen powder and hexapeptide-9 can be mixed in any proportion. Further optionally, the total mass percentage of hydrolyzed collagen powder (CHONDRUS CRISPUS) and hexapeptide-9 in the above-mentioned mixture solution is 0.1% to 0.3% by mass.

[0049] Optionally, in some embodiments of this disclosure, the mass ratio of hydrolyzed collagen powder to hexapeptide-9 is 1:(0.1-2).

[0050] For example, in some embodiments of this disclosure, the mass ratio of hydrolyzed collagen powder to hexapeptide-9 is 1:0.1, 1:0.5, 1:1, 1:1.5, 2:1, or any two of the aforementioned values.

[0051] Water, glycerol, sodium PCA, erythritol, xanthan gum, hydrolyzed collagen, benzoic acid, and sorbic acid in the aforementioned mixture of hydrolyzed collagen powder and hexapeptide-9 are all used as solvents, and their respective contents and ratios are not limited; they can be added according to actual needs.

[0052] For example, in some embodiments of this disclosure, the mixture of hydrolyzed collagen and hexapeptide-9 described above can be made from a raw material with the trade name Natriance Ageles extract.

[0053] Furthermore, in some embodiments of this disclosure, the anti-wrinkle cream further includes: a primary emulsifier; the primary emulsifier is a low-melting-point C12-20 acid PEG-8 ester.

[0054] In the above technical solution, the anti-wrinkle cream uses low-melting-point C12-20 acid PEG-8 ester, which can be combined with the aforementioned functional ingredients. This not only enhances the anti-wrinkle effect of the entire anti-wrinkle cream, but also allows the cream to melt quickly upon contact with the skin, thus improving skin absorption.

[0055] Furthermore, in some embodiments of this disclosure, the anti-wrinkle cream further includes at least one of shea butter and cetearyl alcohol.

[0056] In the above technical solution, the anti-wrinkle cream, by compounding shea butter and cetearyl alcohol, can further achieve a synergistic effect with low-melting-point C12-20 acid PEG-8 ester, further enhancing the characteristic of the entire anti-wrinkle cream melting quickly upon contact with the skin, thereby facilitating skin absorption.

[0057] Furthermore, in some embodiments of this disclosure, the anti-wrinkle cream further includes: isononyl isononanoate, polydimethylsiloxane, and ammonium acryloyldimethyltaurate / VP copolymer.

[0058] In the above technical solution, the oil phase of the anti-wrinkle cream is mainly composed of isononyl isononanoate and polydimethylsiloxane, combined with the main thickener of the system, Aristoflex AVC (ammonium acryloyl dimethyl taurate / VP copolymer), which can work synergistically with the aforementioned main emulsifier to make the anti-wrinkle cream have a light texture and silky feel; thus, it is beneficial to the skin feel of the anti-wrinkle cream and to the skin absorption effect.

[0059] Further, optionally, in some embodiments of this disclosure, the composition of the above-mentioned anti-wrinkle face cream is as shown in Table 1 below:

[0060] Table 1 Anti-wrinkle face creams

[0061] In the table above, the mass percentage of *Codonopsis pilosula* extract in ingredient #26 is 0.2%; the mass percentage of conotoxin in ingredient #27 is 0.2%; the mass percentage of soluble collagen in ingredient #28 is 0.2%; and the total mass percentage of hydrolyzed collagen and hexapeptide-9 in ingredient #29 is 0.2%, with a mass ratio of 1:1. In some embodiments of this disclosure, the above-mentioned anti-wrinkle cream is prepared according to the following steps:

[0062] Preparation process:

[0063] 1. Pre-processing (A): Add raw material (19) from Table 1 above to raw material (20), and disperse evenly with an external homogenizer until there are no particles.

[0064] 2. After adding raw material (1) to the water phase pot, start stirring at 1000 rpm. After adding raw materials (2), (3), (4), (5), (6), (7) and (8), heat to 80-85℃ and keep warm for 5-20 minutes.

[0065] 3. After adding the raw materials (9), (10), (11), (12), (13), (14), (15), (16) and (17) to the oil phase pot, turn on the stirring at 1000 rpm, heat to 80-85℃, and keep warm for 5-15 minutes;

[0066] 4. Pump 3 / 4 of the aqueous phase material into the emulsifying pot, turn on the maximum stirring of the emulsifying pot, pump the oil phase material into the emulsifying pot, and then pump the remaining 1 / 4 of the aqueous phase material into the emulsifying pot. Vacuum -(0.03-0.05)Mpa, turn on the external circulation to homogenize for 3-8 minutes at 3000rpm. After homogenization, add (18) and start cooling.

[0067] 5. Reduce the stirring speed to 55 rpm and cool to 40-45℃. Add (21), (22), (23), (24), (25), (26), (27), (28), (29) and pre-made (A). Maintain vacuum stirring for 5-15 minutes.

[0068] 6. Take samples for testing. If the samples pass the test, filter them through a 100-mesh filter cloth at 35-40℃ (do not store in metal containers).

[0069] This disclosed anti-wrinkle cream features an innovative combination of bicyclic peptides; it is also formulated with recombinant dual collagen and marine collagen oligopeptides, achieving multi-dimensional anti-wrinkle and wrinkle-reducing effects (promoting collagen production, increasing SPARC in the dermis, increasing fibrin levels in the dermis, inhibiting the transmission of skin nerve signals, and inhibiting the activity of collagenase), effectively inhibiting skin aging. Furthermore, the disclosed anti-wrinkle cream has a lightweight texture, a superior silky feel upon application, melts quickly upon contact with the skin, absorbs rapidly, is non-sticky, and provides excellent moisturizing. Moreover, by incorporating the aforementioned emulsifiers and oil phase, this anti-wrinkle cream is gentle and non-irritating, with a better skin feel, and the ingredients are natural and environmentally friendly, causing no harm to human skin.

[0070] The features and performance of this disclosure will be further described in detail below with reference to embodiments:

[0071] Example 1

[0072] An anti-wrinkle face cream is provided, the composition of which is shown in Table 2 below:

[0073] Table 2

[0074] In the table above, the mass percentage of Codonopsis pilosula extract in ingredient No. 26 is 0.2%; the mass percentage of conotoxin in ingredient No. 27 is 0.2%; the mass percentage of soluble collagen in ingredient No. 28 is 0.2%; and the total mass percentage of hydrolyzed collagen and hexapeptide-9 in ingredient No. 29 is 0.2%, with a mass ratio of 1:1.

[0075] Preparation process:

[0076] 1. Pre-processing (A): Add raw material (19) from Table 2 to raw material (20), and disperse evenly with an external homogenizer until there are no particles.

[0077] 2. After adding raw material (1) to the water phase pot, start stirring at 1000 rpm. After adding raw materials (2), (3), (4), (5), (6), (7) and (8), heat to 85℃ and keep warm for 10 minutes.

[0078] 3. After adding the raw materials (9), (10), (11), (12), (13), (14), (15), (16) and (17) to the oil phase pot, turn on the stirring, turn the speed to 1000 rpm, heat to 85℃, and keep warm for 10 minutes;

[0079] 4. Pump 3 / 4 of the aqueous phase material into the emulsifying pot, turn on the maximum stirring of the emulsifying pot, pump the oil phase material into the emulsifying pot, and then pump the remaining 1 / 4 of the aqueous phase material into the emulsifying pot. Vacuum -0.04Mpa, turn on the external circulation to homogenize for 5 minutes at 3000rpm. After homogenization, add (18) and start cooling.

[0080] 5. Reduce the stirring speed to 55 rpm and cool to 45°C. Add raw materials (21), (22), (23), (24), (25), (26), (27), (28), (29) and pre-made (A), and maintain vacuum stirring for 10 min.

[0081] 6. Take samples for testing. If the samples pass the test, filter them at 40℃ using a 100-mesh filter cloth (do not store in metal containers).

[0082] [Mildness Test]

[0083] 1. Patch test

[0084] 1.1. Materials and Methods

[0085] (1) Test substance: Anti-wrinkle face cream sample from Example 1

[0086] (2) Negative control: Blank control

[0087] (2) Subjects: 30 (1 male and 29 females, aged 20-60 years)

[0088] (3) Patch Method: Place 0.020-0.025 ml of the test substance into a patch applicator, apply it externally to the inside of the subject's arm with hypoallergenic adhesive tape, remove the test substance after 24 hours, and observe the skin reaction at 0.5 hours, 24 hours, and 48 hours. Record the results according to the skin reaction grading standards in Chapter 7 of the 2015 edition of the "Cosmetic Safety Technical Specifications" for human patch experiments.

[0089] 1.2 Grading of adverse skin reactions (see Table 3)

[0090] Table 3

[0091] 1.3 The results of the patch test are shown in Table 4.

[0092] Table 4

[0093] 1.4 Experimental Conclusions

[0094] The prepared repair cream sample was tested using a patch test after adding each ingredient according to the maximum dosage in the anti-wrinkle cream formula. The scores of 30 subjects were all 0 after 0.5h, 24h, and 48h following the removal of the test substance patch. The scores of the negative control patch were also 0 after 0.5h, 24h, and 48h following the removal of the negative control patch. This indicates that the anti-wrinkle cream is gentle and non-irritating.

[0095] Example 2

[0096] An anti-wrinkle face cream is provided, the composition of which is shown in Table 5; the preparation process is the same as that in Example 1.

[0097] Table 5

[0098] In the table above, the mass percentage of Codonopsis pilosula extract in ingredient No. 26 is 0.2%; the mass percentage of conotoxin in ingredient No. 27 is 0.2%; the mass percentage of soluble collagen in ingredient No. 28 is 0.2%; and the total mass percentage of hydrolyzed collagen and hexapeptide-9 in ingredient No. 29 is 0.2%, with a mass ratio of 1:1.

[0099] Example 3

[0100] An anti-wrinkle face cream is provided, which differs from Example 2 in that: the content of ingredient No. 27 is 1.0; the content of ingredient No. 28 is 0.1; the content of ingredient No. 29 is 1.0; and the rest are the same.

[0101] Comparative Example 1

[0102] A face cream is provided, the composition of which is shown in Table 6; the preparation process is the same as in Example 1.

[0103] Table 6

[0104] Comparative Example 2

[0105] A face cream is provided, which differs from Example 2 in that the content of ingredient No. 26 is 0; all other aspects are the same.

[0106] Comparative Example 3

[0107] A face cream is provided, which differs from Example 2 in that the content of ingredient No. 27 is 0; all other ingredients are the same.

[0108] Comparative Example 4

[0109] A face cream is provided, which differs from Example 2 in that the content of ingredient No. 28 is 0; all other aspects are the same.

[0110] Comparative Example 5

[0111] A face cream is provided, which differs from Example 2 in that the content of ingredient No. 29 is 0; all other ingredients are the same.

[0112] [Anti-wrinkle efficacy test]

[0113] The anti-wrinkle efficacy of the face creams from Example 2 and Comparative Example 1 was tested.

[0114] Test plan:

[0115] (1) Test objective

[0116] A pre- and post-contrast test was conducted. Using a non-invasive testing method, the Evaskin-S5 took photos and analyzed the number, volume, and area of ​​nasolabial folds and frown lines to evaluate the product's anti-wrinkle effect.

[0117] (2) Product Use

[0118] 2.1 Application area: Face

[0119] 2.2 How to use: After cleansing your face every morning and evening, take an appropriate amount of anti-wrinkle cream in your palm, apply it evenly to your entire face, gently pat until absorbed, and then gently lift and massage upwards until fully absorbed.

[0120] 2.3 Usage period: 28 days

[0121] (3) Selection criteria:

[0122] I. Healthy Chinese women;

[0123] II. Age 30 to 60 years old;

[0124] III. The face has nasolabial folds and frown lines;

[0125] IV. Subjects who are currently using hormone replacement therapy or hormones to control fertility should be able to maintain their original usage habits during the trial period, and subjects who are not using such hormones should ensure that they do not use such hormones during the trial period;

[0126] V. No allergic diseases, and no history of allergies to cosmetics or other topical preparations;

[0127] VI. Participants must voluntarily participate in the trial, abide by the trial requirements, and provide timely feedback if they experience any discomfort.

[0128] (4) The test content is shown in Table 7.

[0129] Table 7

[0130] (5) Test Results

[0131] I. Each subject used the test product of each embodiment or comparative example for 28 days. The instrument test results are shown in Table 8:

[0132] Table 8

[0133] The data in the table above shows that:

[0134] After using the test product of this disclosure for 28 days, the number, area, and volume of nasolabial folds and the number, area, and volume of frown lines were significantly improved compared with before use, thus demonstrating that the anti-wrinkle cream of this disclosure has significant anti-wrinkle effects.

[0135] The comparison product showed almost no improvement in the number, area, or volume of nasolabial folds and frown lines before and after use, indicating that the comparison product has no anti-wrinkle effect.

[0136] The comparison between Comparative Examples 2-5 and Example 2 shows that the mixture of four active ingredients in the anti-wrinkle cream of this disclosure—Codonopsis pilosula cyclic peptide, Conophytum oxyphylla cyclic peptide, Pichia pastoris recombinant collagen, hydrolyzed collagen, and hexapeptide-9—work synergistically to achieve a synergistic effect and greatly improve the anti-wrinkle efficacy.

[0137] The above description is merely a preferred embodiment of this disclosure and is not intended to limit this disclosure. Various modifications and variations can be made to this disclosure by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this disclosure should be included within the scope of protection of this disclosure. Industrial applicability

[0138] This disclosure provides an anti-wrinkle cream with an innovative combination of bicyclic peptides; it also incorporates recombinant double collagen and marine collagen oligopeptides to achieve multi-dimensional anti-wrinkle and wrinkle-reducing effects, including: promoting collagen production, increasing SPARC in the dermis, increasing fibrin levels in the dermis, inhibiting the transmission of skin nerve signals, and inhibiting the activity of collagenase; thereby effectively improving the efficacy of inhibiting skin aging.

Claims

1. An anti-wrinkle face cream, characterized in that, The anti-wrinkle cream comprises, by weight percentage: 0.3%-2.5% of Codonopsis pilosula cyclic peptide solution, 1.0%-5.0% of Conophytum comosum cyclic peptide solution, 0.1%-5.0% of Pichia pastoris recombinant collagen solution, and 1.0%-5.0% of a mixed solution of hydrolyzed collagen and hexapeptide-9.

2. The anti-wrinkle face cream according to claim 1, characterized in that, The anti-wrinkle cream comprises, by weight percentage: 0.5%-2.0% of Codonopsis pilosula cyclic peptide solution, 1.5%-4.0% of Conophytum comosum cyclic peptide solution, 0.5%-4.0% of Pichia pastoris recombinant collagen solution, and 1.5%-5.0% of a mixed solution of hydrolyzed collagen and hexapeptide-9.

3. The anti-wrinkle face cream according to claim 1, characterized in that, The Codonopsis pilosula cyclic peptide solution comprises: glycerin, water, and Codonopsis pilosula extract; Optionally, the mass percentage of the Codonopsis pilosula extract in the Codonopsis pilosula cyclic peptide solution is 0.1% to 0.3%.

4. The anti-wrinkle face cream according to claim 1, characterized in that, The conocoid peptide solution comprises: water, 1,2-pentanediol, 1,2-hexanediol, and conocoid peptide; Optionally, the mass percentage of conopodeptide in the conopodeptide solution is 0.1% to 5%.

5. The anti-wrinkle face cream according to claim 1, characterized in that, The Pichia pastoris recombinant collagen solution comprises: water, glycerol, sodium dihydrogen phosphate, disodium hydrogen phosphate, and soluble collagen; Optionally, the soluble collagen in the Pichia pastoris recombinant collagen solution is 0.1% to 5% by mass.

6. The anti-wrinkle face cream according to claim 5, characterized in that, The recombinant Pichia pastoris collagen uses amino acids 1076-1202 of human type I collagen and amino acids 594-846 of type III collagen as templates for human collagen.

7. The anti-wrinkle face cream according to claim 1, characterized in that, The mixed solution of hydrolyzed collagen and hexapeptide-9 comprises: water, glycerol, sodium PCA, erythritol, carrageenan powder, xanthan gum, hydrolyzed collagen, hexapeptide-9, benzoic acid, and sorbic acid; Optionally, the total mass percentage of the hydrolyzed collagen and the hexapeptide-9 in the mixed solution is 0.1% to 5%.

8. The anti-wrinkle face cream according to any one of claims 1-7, characterized in that, The anti-wrinkle cream also includes: a primary emulsifier; the primary emulsifier is a low-melting-point C12-20 acid PEG-8 ester.

9. The anti-wrinkle face cream according to any one of claims 1-7, characterized in that, The anti-wrinkle cream also includes: shea butter and cetearyl alcohol.

10. The anti-wrinkle face cream according to any one of claims 1-7, characterized in that, The anti-wrinkle cream also includes: isononyl isononanoate, polydimethylsiloxane, and ammonium acryloyldimethyltaurate / VP copolymer.

Images